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Abstract
Background: The extracellular matrix plays an important role in tissue regeneration. We investigated whether extracellular
matrix protein fragments could be targeted with antibodies to ischemically injured myocardium to promote angiogenesis
and myocardial repair.
Methodology/Principal Findings: Four peptides, 2 derived from fibronectin and 2 derived from Type IV Collagen, were
assessed for in vitro and in vivo tendencies for angiogenesis. Three of the four peptides—Hep I, Hep III, RGD—were
identified and shown to increase endothelial cell attachment, proliferation, migration and cell activation in vitro.B y
chemically conjugating these peptides to an anti-myosin heavy chain antibody, the peptides could be administered
intravenously and specifically targeted to the site of the myocardial infarction. When administered into Sprague-Dawley rats
that underwent ischemia-reperfusion myocardial infarction, these peptides produced statistically significantly higher levels
of angiogenesis and arteriogenesis 6 weeks post treatment.
Conclusions/Significance: We demonstrated that antibody-targeted ECM-derived peptides alone can be used to sufficiently
alter the extracellular matrix microenvironment to induce a dramatic angiogenic response in the myocardial infarct area.
Our results indicate a potentially new non-invasive strategy for repairing damaged tissue, as well as a novel tool for
investigating in vivo cell biology.
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Introduction
Recent advances in the field of stem cell therapy have renewed
enthusiasm for the prospects of myocardial regeneration and
repair. Much research has been dedicated into fully assessing the
potential of cell therapy in promoting tissue regeneration.
However, certain hurdles need to be resolved in order to optimize
cell therapy for myocardial regeneration. One of these challenges
involves providing the cells a sufficient environment for proper
engraftment, sustainability and induction of differentiation [1,2].
The extracellular matrix (ECM) plays an important role in cell
engraftment and tissue regeneration. The development of
biocompatible scaffolds acting as an extracellular matrix to serve
as a substrate for sustaining cell growth, survival, differentiation,
and other biologically relevant functions has become an integral
aspect of tissue engineering. In this study, we hypothesized that an
in vivo matrix could be formed by targeting ECM fragments to an
area of myocardial injury and facilitate myocardial repair. To test
this hypothesis, we determined whether the composition of the
ECM in the region of a myocardial infarct could be altered to
promote neovascularization.
Even in the presence of angiogenic cytokines such as vascular
endothelial growth factor (VEGF), endothelial cells (ECs) require
adhesion to the ECM to facilitate migration. Migration of ECs
plays an important role in angiogenesis via sprouting of new blood
vessels from the existing vasculature [3]. The maturation of vessels
is dependent on the establishment of a continuous basement
membrane [4]. The ECM, which consists of structural proteins
(e.g. collagen), adhesive proteins (e.g. fibronectin, FN), anti-
adhesive proteins (e.g. tenascin), and proteoglycans [5], plays a
pivotal role in the activation of various intracellular signaling
pathways that are involved in cell migration, survival, prolifera-
tion, differentiation, and angiogenesis [6]. The composition of the
ECM is constantly changing in order to direct the growth,
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instance, in the early stages of angiogenesis, type IV collagen (Col
IV) appears in patchy subendothelial deposits, which correlates
with lumen formation and maintenance, but in the later stages Col
IV appears as a continuous mesh, which may act to prevent
vascular regression and promote maintenance of the newly formed
vessel [7,8,9]. Additionally, it has been suggested that degradation
of the basement membrane facilitates exposure to collagen and
fibrinogen to encourage sprouting and initiation of capillary
morphogenesis with the maturation of the vessel lumen occurring
with the re-establishment of the intact basement membrane [3].
Here, we investigated whether functional groups derived from
Col IV [10,11,12] and FN [13,14,15,16] (Table 1) could
sufficiently alter the microenvironment to favor neovasculariza-
tion. Col IV is a major component of the basement membrane and
has been shown to promote and regulate the formation,
elongation, and stabilization of microvessels during angiogenesis
[7]. FN is a major component of the ECM and is known to be
involved in promoting wound healing by recruiting endothelial or
epithelial cells to the site of injury [17]. The ECM-derived
functional groups were chemically conjugated to a monoclonal
antibody targeting an injury-specific antigen within the MI,
thereby allowing us to non-invasively deliver the ECM to the site
of injury.
Results
In vitro cell attachment, proliferation, and migration
To investigate the biological activity of the ECM peptides, the
peptides were compared to their full length protein in cell adhesion
and cell proliferation assays. The RGD and HepIII peptides
showed initial cell adhesion significantly better relative to wells
treated with only phosphate buffered saline (PBS) (Figure 1a–b).
Cell proliferation (Figure 1c–d) was observed for HepI, HepIII,
and RGD, but not for FC/HV.
Gradients of immobilized ECM components have been shown
to drive haptotactic migration in vitro, which is not dependent on
cytokines [18,19]. Although the importance of this ability has not
been fully assessed, it stands to reason that, in vivo, higher
concentrations of certain ECM components encountered by
endothelial cells during new vessel formation may direct their
recruitment and outward migration partly via haptotaxis [3].
Hence, we sought to assess the peptides’ ability to recruit cells by
looking at their ability to induce haptotactic migration (Figures 1e–
f). Peptides HepI, HepIII, and RGD promoted haptotactic
migration, but to a lesser extent compared to their protein
counterparts. Migration was better with HepIII than with HepI.
Both HepIII and RGD were able to promote statistically
significant migration, as determined by the area cell density,
when compared to the membrane coated with only PBS even at
concentrations as low as 0.5 mg/mL. For HepI, the migration was
statistically significantly higher at concentrations $1 mg/mL. No
migration was observed with FC/HV.
Cell morphology on the various peptide coatings were
compared to their source protein counterparts (Figure S1). Only
cells with round morphology were observed on the PBS-treated
dishes, indicating that they had not properly adhered to the dish
surface. Cell morphology on dishes coated with RGD, HepI, or
HepIII was similar to the cell morphology on the Col IV- or FN-
coated dishes, i.e. spread out cells, indicating adherence to the dish
surface. There were some adherent cells after 24 hours of
incubation in the FC/HV-coated dishes, but these adherent cells
were no longer observed in subsequent days.
Activation of Erk1/2 by ECM peptides
All ECM peptides induced, although to varying degrees,
activation(Figure 1g) —i.e. phosphorylation—of extracellular
signal-regulated kinase 1/2 (Erk1/2), which is involved in the
signaling pathway leading to angiogenesis and arteriogenesis [20].
We saw no activation of Erk1/2 for cells cultured on the PBS-
treated dishes.
Antibody targeting of ECM peptides to MI
To test whether we could direct the ECM-derived peptides to
the injured myocardium, HepIII was conjugated to anti-rat
cardiac a-myosin heavy chain (anti-MHC) using carbodiimide
chemistry. Two days post-MI, either HepIII conjugated to the
antibody (Ab-HepIII) or PBS (control) were injected via the
external jugular vein into Sprague-Dawley rats, who were
sacrificed 24 hours later. We stained for the presence of the
antibody (Ab) using Mouse-on-rat HRP-polymer (Biocare Medi-
cal, Concord, CA). We observed positive staining (dark brown)
within the MI for the Ab-HepIII-treated heart (Figure 2b). In
addition, we had used FITC-labeled peptides. Under fluorescent
microscopy, we were able to confirm that the peptides were also
present within the MI (Figure 2c), verifying that conjugating the
peptide to the Ab allowed us to successfully target the peptide to
the MI.
A series of in vitro control studies to assess the functional
behavior of the peptides conjugated to the Ab (Ab-peptides) also
were performed (data not shown). Ab-RGD and Ab-HepIII
promoted significantly more initial cell attachment compared to
PBS control. Ab-HepI, Ab-HepIII, and Ab-RGD also demon-
strated significantly increased proliferation and migration com-
pared to PBS and Ab only controls. Hence, in the case of initial
cell attachment and cell migration, there did not appear to be any
significant difference between Ab-HepI, Ab-HepIII, Ab-RGD and
their unconjugated counterparts. These results are in agreement
with previously published reports, suggesting that conjugation of
an ECM peptide to ovalbumin or a polymer matrix did not
negatively affect its ability to promote cell attachment, prolifera-
tion, and migration [10,11,14,15,16]. Also, endotoxin analysis of
the Ab-peptides showed that their endotoxin levels were
,0.06 EU/mL, below the FDA limits of 0.5 EU/mL [21].
Targeted ECM peptides induce angiogenesis
Assessment of capillary formation in the infarct region
(Figure 3a), showed that rats treated with Ab-HepI (373693
capillaries/mm
2), Ab-HepIII (359661 capillaries/mm
2), or Ab-
RGD (373670 capillaries/mm
2) had statistically significantly
higher capillary density compared either to the PBS treatment
group (196654 capillaries/mm
2) or to Ab-FC/HV (255636
capillaries/mm
2). There was no statistical difference in capillary
density among rats treated with Ab-HepI, Ab-HepIII, or Ab-
RGD. Rats treated with Ab only (185634 arterioles/mm
2) did not
Table 1. Sequence of the peptides along with their source
protein.
Peptide Name Sequence Protein of Origin
HepI [10,12] TAGSCLRKFSTMY-OH Collagen IV
HepIII [10,11] GEFYFDLRLKGDKY-OH Collagen IV
FC/HV [13,16] WQPPRARI-OH Fibronectin
RGD [14,15] GRGDSPASSPISC-OH Fibronectin
doi:10.1371/journal.pone.0010384.t001
Peptides Promote Angiogenesis
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treatment group. Both the Ab only and the PBS treatment groups
served as negative controls.
Arteriogenesis (Figure 3b) in rats treated with Ab-HepI (1062
arterioles/mm
2), Ab-HepIII (961 arterioles/mm
2), or Ab-RGD
(1062 arterioles/mm
2) showed statistically significantly higher
arteriole density when compared to the PBS treatment group (562
arterioles/mm
2) or to Ab-FC/HV (761). There also was no
statistical difference in the arteriole density among rats treated
with Ab-HepI, Ab-HepIII, or Ab-RGD. We observed no
Figure 1. In vitro assays. (a) and (b) Cell adhesion was assessed after 30 minutes of incubation in wells coated with peptides at 20 mg/mL, 50 mg/
mL, and 100 mg/mL. The absorbance readings were normalized to either 100 mg/mL FN or 100 mg/mL Col IV, depending on the peptide’s source
protein, to allow for comparison. * P,0.05. (c) and (d) Cell proliferation was also assessed with peptides at 20 mg/mL, 50 mg/mL, and 100 mg/mL at
Day 1 (white), Day 2 (gray), and Day 3 (black). The absorbance readings again were normalized to either 100 mg/mL FN or 100 mg/mL Col IV,
depending on the peptide’s source protein. (e) and (f) Haptotactic migration at various peptide or protein concentrations. The area cell densities
have been normalized to allow for comparison. (g) Western blot analysis showed phosphorylation of Erk1/2 in cells grown on HepI, HepIII, Col IV,
RGD, FC/HV, and FN (Wells 1–6, respectively). No phosphorylated Erk1/2 band was seen for cells grown on PBS-treated dishes (Well 7). Total Erk1/2
was present in the cells grown under all the conditions. b-tubulin was used as an internal control.
doi:10.1371/journal.pone.0010384.g001
Peptides Promote Angiogenesis
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treated with Ab only (561 arterioles/mm
2).
To determine if the newly formed vessels were contiguous with
the existing vasculature, we used previously established protocols
whereby we perfused the hearts with fluorescently labeled
microbeads [22,23]. In Figure 4 we show overlaid high
magnification images of regions within the myocardial infarct
showing the fluorescent microbeads, indicated in green, within the
lumen of the arterioles stained immunofluorescently using anti-a-
smooth muscle actin. The presence of the microbeads indicated
that the observed arterioles in the infarct region were functionally
connected to pre-existing vessels.
Both Masson’s trichrome- and hemotoxylin-and-eosin- (H&E)
stained slides were used to assess infarct size. We did not find a
statistically significant difference in the mean infarct size when
compared to the PBS treatment group (Figure 3c).
Affects of Targeted ECM peptides on LV function
The functional effects of treatment with Ab-peptide were
investigated by echocardiography at baseline (1–2 days post MI
and before treatment) and 6 weeks after treatment (Table 2). LV
ejection fraction and wall thickness significantly decreased in the
control groups, while LV dilation significantly increased in the
control groups, all of which were indicators of worsening LV
function. Only HepIII treatment prevented the negative LV
remodeling affects following the MI.
Discussion
Our results demonstrate that antibody targeting of ECM-
derived peptides to ischemically injured myocardium can
effectively help to produce an ECM favorable for angiogenesis.
A critical barrier to tissue regeneration is the lack of an adequate
vascular network. The creation of a vascular bed in the infracted
myocardium should allow for greater cell engraftment and survival
[24,25]. Therefore, this strategy of specifically targeting ECM-
derived peptides to the ischemic myocardium may provide a more
favorable microenvironment for cell transplantation and myocar-
dial regeneration. The use of the ECM-derived peptides alone,
without growth factors or cells, was sufficient to promote an
angiogenic response in infarcted rat hearts. The induction of new
vessel formation suggests that targeting active components of the
Figure 2. Immunostaining for Ab-HepIII in the infarct region.
Hearts from rats sacrificed on 1 day after injection. The rats were
injected intravenously with either (a) PBS or (b) the Ab-HepIII 1 day
post-MI. The presence of the Ab is indicated by the brown stain. For the
sake of clarity, we have outlined the infarct region. At high
magnification, we were also able to see fluorescence within the infarct
region(c), as indicated by the arrow, of the FITC-labeled peptides
(indicated in black).
doi:10.1371/journal.pone.0010384.g002
Figure 3. Increased neovascularization within the MI region. (a)
Capillary staining showed significantly higher capillary density for rats
treated with Ab-HepI, Ab-HepIII, or Ab-RGD. { P,0.05 vs. PBS, { P,0.05
vs. Ab-FC/HV. (b) Arteriole staining also showed significantly higher
arteriole density for rats treated with Ab-HepI, Ab-HepIII, or Ab-RGD. {
P,0.05 vs. PBS, { P,0.05 vs. Ab-FC/HV. (c) Infarct size measurements
showed no statistically significant differences between the treatment
groups and the PBS treatment group.
doi:10.1371/journal.pone.0010384.g003
Peptides Promote Angiogenesis
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act as its own bioreactor to regenerate vital structures of the
myocardium.
The MHC antibody specifically targets the ECM peptides to the
MI region in the heart (Figure S2). Nuclear imaging studies using
I
125-radiolabeled MHC-Ab showed that the majority of the MHC-
Ab was concentrated within the MI of the heart and was still
detectable within the MI 1 week post-injection. Unconjugated
I
125-radiolabeled peptides injected into the rats 1 day post-MI
were detectable within the heart 3 hours post-injection, but only at
trace levels 24 hours post-injection. Additionally, biodistribution
analysis showed that the unconjugated peptides were predomi-
nantly in other organs—e.g. liver, intestines—instead of the heart
(Figure S3). Not only did the MHC-Ab concentrate the peptides
within the MI, but it also allowed the peptides to remain within the
MI for longer periods of time. Hence, in order to expect any
benefit from peptide treatment after acute MI, it was necessary for
us to target them with an antibody. However, even though most of
the antibody was targeted to the infarct region of the heart, there
were still trace levels in other organs, which could result in
neoplastic angiogenesis within these organs. Future studies will
need to be conducted to fully assess the effect of these trace levels
in other organ systems in producing angiogenesis.
Our in vitro data found three peptides—HepI, HepIII, RGD—
that exhibited similar properties, although to a lesser extent, as
their source proteins, particularly in terms of promoting
Figure 4. Microbead perfusion. High magnification (406) images
within the MI region showing the perfusion of 0.2 mm fluorescent
microbeads (green) into arterioles that have been stained using anti-a
smooth muscle actin (orange) in hearts treated with (a) Ab-FC/HV, (b)
Ab-RGD, (c) Ab-HepI, or (d) Ab-HepIII. Scale bar: 15 mm.
doi:10.1371/journal.pone.0010384.g004
Table 2. Echocardiography data showing the internal comparisons between measurements taken before injection (baseline) and
6 weeks after injection.
Measured Parameters Treatment Baseline 6 weeks post P
Ejection fraction, % Ab-HepI 38.662.81 34.162.83 0.0068
Ab-HepIII 38.866.00 35.563.41 0.184
Ab-RGD 41.264.16 33.864.57 0.000186
Ab-FC/HV 39.463.47 32.561.61 0.000000629
Ab only 40.861.73 31.065.53 0.0023
PBS 39.662.91 31.664.00 0.000425
LV diastolic volume, mL Ab-HepI 0.560.1 0.760.1 0.00008
Ab-HepIII 0.560.1 0.760.1 0.004
Ab-RGD 0.460.1 0.760.1 0.000001
Ab-FC/HV 0.560.1 0.860.1 0.00006
Ab only 0.560.04 0.860.1 0.00005
PBS 0.560.1 0.760.1 0.002
LV systolic volume, mL Ab-HepI 0.360.1 0.560.1 0.00007
Ab-HepIII 0.360.1 0.560.1 0.002
Ab-RGD 0.360.1 0.560.1 0.000001
Ab-FC/HV 0.360.1 0.560.1 0.000003
Ab only 0.360.0 0.660.1 0.00002
PBS 0.360.1 0.560.1 0.003
Infarct wall thickness, cm Ab-HepI 0.2260.016 0.1960.018 0.0083
Ab-HepIII 0.2160.014 0.1760.023 0.00018
Ab-RGD 0.2160.014 0.1760.013 0.021
Ab-FC/HV 0.2160.017 0.1660.029 0.0044
Ab only 0.2260.024 0.1460.015 0.000001
PBS 0.2160.013 0.1560.016 0.000000056
doi:10.1371/journal.pone.0010384.t002
Peptides Promote Angiogenesis
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Nanogram amounts of either HepIII or RGD were sufficient to
promote significant movement of endothelial cells. This is the
same order of magnitude of peptides that we injected into our rats.
Using fluorescently labeled peptides, we had determined that our
conjugation resulted in crosslinking ,3 moles of peptide per mole
of antibody. The presence of the ECM-derived peptides could
promote the migration of endothelial cells to the infarct site.
Cells interact with the ECM via receptors, including integrins.
Yet, these receptors only interact with certain regions of an ECM
protein. Our Western blot analysis showed activation of Erk1/2 by
HepI, HepIII, and RGD. Activation of the Erk1/2 signal
transduction pathway in ECs is critical for EC proliferation and
angiogenesis [26,27,28,29]. HepIII has been shown to interact
with a2b1 and a3b1 integrins, thereby promoting cell adhesion to
the peptide [11,30]. There is some evidence that a2, a3, and b1
integrin subunits can also interact with HepI [11]. RGD has been
shown to interact with the integrin avb3 [31,32,33]. Endothelial
cells migrate via avb3 integrins. The interaction of the cells via
these integrins can trigger a cascade of signal transduction
pathways, some of which could be involved in initiating
angiogenesis and/or arteriogenesis. For instance, avb3 is involved
in the signaling of fibroblast growth factor 2 (FGF2), which is
involved in various signaling pathways, including the activation of
Erk1/2, which in turn activates the signaling pathways for
angiogenesis and/or arteriogenesis [20]. Integrin a2b1 has been
shown to support VEGF-stimulated signal transduction [19],
which also includes Erk1/2 activation. Integrin a3b1-mediated
adhesion has been shown to activate focal adhesion kinase (FAK)
as well as Erk in keratinocytes [34]. Even though HepI, HepIII,
and RGD did not promote activation of Erk1/2 to the same
extent, their induced angiogenic responses in terms of capillary
and arteriole formation were similar. This suggests that in addition
to Erk1/2 activation, the ability to induce cell migration and cell
proliferation are characteristics that are important if not more so
in the promotion of the observed arteriogenesis and angiogenesis.
Furthermore, the ECM peptides may be influencing new vessel
formation by interacting with other ECM proteins. Interestingly,
HepIII peptides can interact with one another to form a polymer-
like matrix (Figure S4). It is possible that a comparable situation is
occurring in rats treated with HepIII and may explain why HepIII
was the only peptide that was able to prevent further negative
remodeling as indicated by the echocardiography data. The
peptides do not necessarily have to be interacting with each other.
They may be able to interact with surrounding ECM proteins in a
similar manner to form a matrix, thus altering the material
properties of the LV and preventing the negative remodeling
associated with a MI [35,36]. Also, earlier studies have shown that
HepI can interact with whole Col IV [12]. The low dissociation
equilibrium constant Kd=1.66 nM, indicates that the binding
affinity of HepI for Col IV is remarkably high. HepI’s ability to
interact strongly with Col IV may in some way help to contribute
to the formation of neovessels in HepI-treated rats, as Col IV is
known to be a major factor in the induction of new vessel
formation and in the stabilization of these new vessels [17].
Despite previous reports [13,16] showing that FC/HV could
promote cell adhesion and migration, we did not observe such
behavior in our studies with FC/HV. Based on our results, the
peptide might promote transient adhesion, as evidenced by our
observation of spread cells 1 day after incubation on FC/HV-
treated plates. Although FC/HV did induce Erk1/2 activation, we
observed no statistically significant increase in angiogenesis or
arteriogenesis in the FC/HV-treated rats. It is possible that FC/
HV is inducing Erk1/2 activation in the cells already present
within the MI region, but the inability of the peptide to promote
significant endothelial cell migration and cell proliferation as
compared to the other 3 peptides studied may limit its ability to
induce any dramatic neovascular formation.
In conclusion, Ab-targeted ECM-derived peptides can be used
to alter the myocardial microenvironment and promote the
induction of angiogenesis in the injury site after a MI. The exact
mechanisms by which the ECM peptides induced the observed in
vivo angiogenic response, however, warrant further study. Fur-
thermore, from our echocardiography data only Hep III
prevented negative remodeling of the LV following a MI,
indicating that neovascularization alone is insufficient to get full
recovery of LV function. Perhaps by combining this ECM peptide
therapy with cell therapy, we may be able to get full restoration of
cardiac function and tissue. Nevertheless, our results present a new
non-invasive strategy for regenerative therapies and a tool for
investigating tissue repair and regeneration.
Materials and Methods
Peptides
The peptides were synthesized by Commonwealth Biotechnol-
ogies Inc. (Richmond, Virginia). Amino acid analysis was
performed on the peptides to verify the amino acid sequence.
The reagents used to crosslink the peptide to the antibody were
purchased from Pierce (Rockford, IL).
Initial cell attachment and proliferation assays
For the adhesion studies, 96-well Immulon 1B plates (Fisher,
Pittsburg, PA) were used. The whole ECM protein from which the
peptide was derived was used as a positive control. PBS-treated
wells were used as a negative control. Since previous studies had
shown that negative versions—e.g. different amino acid sequence
but with the same hydropathy value, truncated, and/or scram-
bled— of the peptides used here abrogated or lessened their ability
to promote cell adhesion and proliferation, we decided not to
include scrambled or truncated versions of the peptides in this
study [12,15,16,37]. 50 mL of the peptide or protein in PBS at
various concentrations was added to each well and allowed to
incubate at 37uC overnight, after which the wells were blocked for
2 hours at 37uC with 2 mg/mL bovine serum albumin (BSA)
solution and later washed twice with PBS before addition of
human umbilical vein endothelial cells (HUVECs; Lonza, Basel,
Switzerland). HUVECs were used because they were readily
available, easily cultured, and frequently used as an in vitro model
for testing angiogenic potential [38,39]. Cell adhesion were
assessed after 30 minutes of incubation at 37uC, 5.0% CO2
followed by treatment with a MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt) tetrazolium/formazan assay (Promega, Madison, WI).
For the proliferation assays, untreated Co-Star 96-well plates
(Fisher, Pittsburg, PA) were used. The coating protocol was the
same as above. Proliferation was measured using a MTS
tetrazolium/formazan assay after 1, 2, and 3 days of incubation
at 37uC, 5.0% CO2.
Haptotactic cell migration
Haptotactic migration was performed in triplicate and was
assessed via a modified Boyden chamber (8 mm pore size, Corning,
Acton, MA) using previously established protocols [40]. In brief,
the lower chamber first was blocked with 10% BSA for at least
30 minutes at 37uC followed by several washings with PBS. The
underside part of the membrane on the upper chamber was coated
with increasing concentrations (0.5–300 mg/mL) of either the
Peptides Promote Angiogenesis
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30 minutes at 37uC and then allowed to air dry at room
temperature under aseptic conditions. Basal cell media (Lonza,
Basel, Switzerland) supplemented with 0.5% BSA was added to
the lower chamber. 100 mL of HUVECs in the same media was
added to the upper chamber. After incubating at 37uC, 5.0% CO2
for 6 hours, the cells on the membrane of the upper chamber were
fixed with 4% paraformaldehyde followed by removal of the cells
on the upper side of the membrane with a Q-tip. Finally, the
membrane was carefully removed from the chamber, dipped in a
solution of a 1:4000 dilution of Hoechst 33342 (Invitrogen,
Carlsbad, CA) and placed on a glass slide. 5 random pictures were
taken of each membrane at 106magnification using fluorescence
microscopy (Nikon Eclipse E800) to determine the area cell
density.
Western blot analysis
Untreated 35 mm CoStar dishes were coated with 100 mg/mL
of peptide or their source protein,blocked with 2 mg/mL BSA
followed by several PBS washes. HUVECs were cultured on these
plates for 3 days. Cells cultured on dishes treated with just PBS
were used as a control. To isolate the protein, the cells were
scraped off the plates using a cell scraper and washed twice with
cold PBS. The cells were incubated in 20–40 mL of NP40 lysis
buffer (Fisher, Pittsburg, PA) supplemented with protease inhibitor
(BD BaculoGold, BD Biosciences, San Diego, CA) for 30 minutes
at room temperature, vortexing every 10 minutes. The cell
membranes were spun the cells down and the supernatant
extracted.
The protein (10 mg/well) was run through a 12% Tris-glycine
SDS-PAGE gel (Invitrogen, Carlsbad, CA) at a constant voltage of
125 V and transferred to the transfer membrane (Hybond-P,
Amersham Biosciences, Piscataway, NJ) at a constant current of
400 mA. The membrane was blocked with 10% milk protein (Bio-
Rad, Hercules, CA) at room temperature, then incubated with the
primary antibody (1:2000 dilution for total Erk1/2, Chemicon,
Temecula, CA; 1:1000 dilution for phospho-Erk1/2, Chemicon;
or 1:400 dilution for b-tubulin, Santa Cruz Biotechnology, Santa
Cruz, CA) overnight at 4uC. After incubating with the secondary
antibody (1:5000 dilution of IgG-HRP, Chemicon, for Erk1/2 and
1:20,000 dilution for b-tubulin) for 1 hour at room temperature,
the membrane was treated with ECL Plus (Amersham Bioscienc-
es). The film was developed using a Konica SRX-101A developer.
To strip the proteins, the membrane was treated with stripping
buffer for 30 minutes at room temperature.
Antibody isolation and peptide conjugation
Anti-MHC was isolated from HB-276 hybridoma (ATCC,
Masassas, VA). The hybridomas were injected into Balb/c mice
for ascites production. The ascites was then run through a column
packed with Protein A beads (Pierce, Rockford, IL). After
dialyzing against sterile PBS, the purity of the antibody was
verified via SDS-PAGE electrophoresis, using 3–8% Tris-Acetate
gel (Invitrogen, Carlsbad, CA), and its concentration was
determined using a Bio-Rad protein assay kit (Bio-Rad, Hercules,
CA).
We conjugated the peptide to the targeting antibody using
carbodiimide chemistry using the 1-ethyl-3-[3-dimethylaminopro-
pyl]carbodiimide hydrochloride (EDC, Pierce, Rockford, IL)
crosslinker. EDC together with sulfo-NHS (Pierce, Rockford, IL)
were first incubated with 2 mg/mL peptide. After exchanging to
sterile PBS via a desalting column, the reacted peptide was
incubated with 1 mg of antibody. Solutions used for the reactions
were sterile filtered and autoclaved prior to use. Endotoxicity of
the Ab-peptide was determined using the limulus amebocyte lysate
(LAL) assay (Lonza, Basel, Switzerland). In vitro cell attachment,
cell proliferation, and haptotactic migration assays were also
performed on the Ab-peptides.
Acute myocardial infarction model
All surgical procedures were approved by the Committee for
Animal Research at the University of California San Francisco.
Female Sprague-Dawley rats (225–250 g) underwent occlusion of
the left anterior descending coronary artery for 25 minutes before
reperfusion as previously described [35,41,42]. The rats were
randomized 1–2 days after MI to either control or treatment
groups, and were given one intravenous injection via the external
jugular vein. 500 ml( ,100 mg of total protein) of Ab-peptide, Ab
only (negative control), or PBS (control) was injected into the rats.
Each group consisted of 10 animals. Transthoracic echocardiog-
raphy was performed 1–2 days post-MI and 6 weeks post-
treatment as previously described [42,43]. Following echocardi-
ography at 6 weeks, the hearts were perfused with fluorescently
labeled microbeads (Molecular Probes, Eugene, OR) according to
previously described protocols [22,23].
Histology, immunohistochemistry, and
immunofluorescence
Immediately after the microbead perfusion, the hearts were
removed, rinsed in cold saline, blotted-dry and fresh frozen in
Tissue Tek O.C.T. freezing medium (Sakura Finetek, Torrance,
CA). The hearts were sectioned into 10 mm slices. Representative
sequential slides were stained with Masson’s trichrome stain and
H&E for determination of infarct size as previously described [35].
Angiogenesis in the infarct was examined by immunohistochem-
ical (IHC) staining with mouse monoclonal anti-CD31 (BD
Biosciences Pharmingen, San Diego, CA) to visualize capillaries
and with mouse monoclonal anti-a-smooth muscle actin (Sigma,
St. Louis, MO) to detect arterioles [44]. The staining assay was
performed using Mouse-on-rat HRP-polymer (Biocare Medical,
Concord, CA) using slides that were sequential to the slides stained
with trichrome and H&E. Capillaries in the infarct region were
identified as a single layer of CD31-positive cells with flattened
morphology. Vessel density was calculated on the basis of 5 high
magnification fields per section that spanned the infarct and
averaged among 5 sections for each sample. Arterioles within or
bordering the infarct were identified as staining positive for a-
smooth muscle actin and as having a visible lumen with a diameter
between 10 and 100 mm [35,45]. Arteriole density was calculated
as the average number of arterioles in the total infarct area, out of
5 representative slides per sample.
Statistical Analysis
Data are presented as mean 6 standard deviation. Cell
adhesion, proliferation, and migration measurements were
compared using the student’s t test. Differences between
echocardiography measurements before and after injection were
compared, using the paired t test. Differences in the echocardi-
ography measurements, infarct size, and vessel counts across
treatment groups were compared, using one-way analysis of
variance ANOVA with Holm’s adjustment. Significance was
accepted as P,0.05.
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